Last updateThu, 29 Dec 2022 2pm

Back You are here: Inicio Biology & biomedicine Technological offers

Synthetic peptides for fighting metastasis related to the interleukin receptor IL13Rα2

The CSIC has developed a peptide capable of inhibiting the signaling of interleukin 13 mediated by the IL13Rα2 alpha receptor, one of the pathways that contribute metastasis according to recent studies. The synthetic peptide, alone or encapsulated, could be used for the control of metastasis of colon cancer and other tumours such as glioblastoma, as well as in pathologies such as asthma, atopic dermatitis or fibrosis, related to the same receptor, although more assays are required to confirm its efectivity in humans.

Read more ...

A fast test for the analysis of oral tolerance to triglycerides

The Instituto de la Grasa of the CSIC and the University of Sevilla have developed a method for analysing oral tolerance to lipids (triglycerides) from the diet, in humans, in only 4 hours. The method is easier and faster than the current ones.

Read more ...

Low cost and reusable wearable sensors

Scientists at the CSIC have developed new portable and non-invasive sensors for monitoring biomarkers such as glucose, lactate or alcohol. They are based on wireless electro chromic and electrochemical sensors, and they can be used to detect metabolites in biological fluids, either human fluids (sweat, urine…) or in fluids derived from food products (e.g., leaking).

Read more ...

Researchers develop an accommodative lens to imitate the crystalline in order to correct the presbyopia

Scientists at the Instituto de Óptica have developed a new intraocular lens, which changes shape to focus on distant and near objects in order to imitate the crystalline lens function. It is the result of the Presbyopia project, funded by the European Research Council (ERC).

Read more ...

Modulating compounds of KChIP2 and its use for the treatment of cardiovascular pathologies

CSIC and UAM have developed compounds that positively modulate protein-protein interactions that involve KChIP2protein. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.

Read more ...